Berry Genomics Co.,Ltd (SHE:000710)
China · Delayed Price · Currency is CNY 9.15
+0.23 (2.58%)
Sep 1, 2026, 3:04 PM CST
Berry Genomics Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 918.61 | 919.28 | 1,059 | 1,129 | 1,343 | 1,370 |
Other Revenue | 10.54 | 10.54 | 19.47 | 21.92 | 24.64 | 52.43 |
| 929.15 | 929.82 | 1,078 | 1,151 | 1,368 | 1,422 | |
Revenue Growth | -4.59% | -13.76% | -6.36% | -15.83% | -3.81% | -7.67% |
Cost of Revenue | 551.29 | 556.11 | 603.72 | 668.26 | 821.85 | 827.75 |
Gross Profit | 377.86 | 373.7 | 474.44 | 483.16 | 546.15 | 594.43 |
Selling, General & Admin | 346.88 | 336.04 | 357.18 | 404.55 | 463.21 | 456.17 |
Research & Development | 106.6 | 104.36 | 95.42 | 110.01 | 106.74 | 128.23 |
Other Operating Expenses | 3.92 | 5.38 | 10.64 | 4.67 | 3.76 | 2.84 |
Operating Expenses | 559.92 | 548.3 | 593.91 | 682 | 671.71 | 640.85 |
Operating Income | -182.06 | -174.6 | -119.47 | -198.84 | -125.56 | -46.41 |
Interest Expense | -9.98 | -9.98 | -9.83 | -16.35 | -17.64 | -20.3 |
Interest & Investment Income | 3.2 | 3.2 | 3.52 | 2.64 | 2.36 | 5.05 |
Currency Exchange Gain (Loss) | 0.57 | 0.57 | -0.77 | -0.55 | -1.62 | 0.38 |
Other Non Operating Income (Expenses) | -7.78 | -6.72 | -2.59 | -0.37 | 2.79 | -5.26 |
EBT Excluding Unusual Items | -199.3 | -187.52 | -129.14 | -213.47 | -139.66 | -66.54 |
Gain (Loss) on Sale of Investments | -9.23 | -6.38 | -40.18 | -82.67 | -144.31 | -49.13 |
Gain (Loss) on Sale of Assets | 3.13 | 5 | 1.74 | -0.01 | -0.35 | 0.26 |
Asset Writedown | -0.25 | -0.25 | -0.65 | -159.38 | -0.07 | -5.16 |
Other Unusual Items | -0.4 | -0.4 | -2.53 | 2.12 | 8.02 | 0.19 |
Pretax Income | -206.06 | -189.56 | -170.76 | -453.42 | -276.37 | -120.38 |
Income Tax Expense | 7.94 | 6.74 | 17.42 | -28.16 | -29.98 | -10.52 |
Earnings From Continuing Operations | -214 | -196.29 | -188.18 | -425.27 | -246.4 | -109.86 |
Minority Interest in Earnings | 0.46 | -0.54 | -4.25 | -1.93 | -2.53 | -0.96 |
Net Income | -213.54 | -196.84 | -192.43 | -427.2 | -248.93 | -110.82 |
Net Income to Common | -213.54 | -196.84 | -192.43 | -427.2 | -248.93 | -110.82 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 354 | 354 | 354 | 354 | 307 | 357 |
Shares Outstanding (Diluted) | 354 | 354 | 354 | 354 | 307 | 357 |
Shares Change | 0.06% | -0.00% | 0.00% | 15.04% | -14.03% | 0.12% |
EPS (Basic) | -0.60 | -0.56 | -0.54 | -1.21 | -0.81 | -0.31 |
EPS (Diluted) | -0.60 | -0.56 | -0.54 | -1.21 | -0.81 | -0.31 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -64.08 | -5.08 | 31.22 | 55.91 | -52.13 | -242.66 |
Free Cash Flow Per Share | -0.18 | -0.01 | 0.09 | 0.16 | -0.17 | -0.68 |
Gross Margin | 40.67% | 40.19% | 44.01% | 41.96% | 39.92% | 41.80% |
Operating Margin | -19.59% | -18.78% | -11.08% | -17.27% | -9.18% | -3.26% |
Profit Margin | -22.98% | -21.17% | -17.85% | -37.10% | -18.20% | -7.79% |
Free Cash Flow Margin | -6.90% | -0.55% | 2.90% | 4.86% | -3.81% | -17.06% |
EBITDA | -120.44 | -111.68 | -42.28 | -98 | -33.42 | 50.94 |
EBITDA Margin | -12.96% | -12.01% | -3.92% | -8.51% | -2.44% | 3.58% |
D&A For EBITDA | 61.62 | 62.92 | 77.19 | 100.84 | 92.13 | 97.35 |
EBIT | -182.06 | -174.6 | -119.47 | -198.84 | -125.56 | -46.41 |
EBIT Margin | -19.59% | -18.78% | -11.08% | -17.27% | -9.18% | -3.26% |
Revenue as Reported | 929.82 | 929.82 | 1,078 | 1,151 | 1,368 | 1,422 |